drugset / Trial / NCT00830193

N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography

NCT00830193

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Critically ill patients frequently undergo contrast enhanced computed tomography (CT) to establish diagnoses and direct management. Contrast agents can disturb kidney function and result in kidney dysfunction. The investigators investigated the effects of high dose N-acetylcysteine (NAC) or placebo, in addition to hydration, in preventing kidney dysfunction following contrast enhanced CT) in critically ill adults in the intensive care units of two teaching hospitals.

Timeline

Start
2002-08
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator N-acetylcysteine Small molecule 10 g Intravenous